Humacyte Stakeholders File 13D/A Amendment

TL;DR

Niklason & Dougan updated their Humacyte stake filing (13D/A) on May 31st. Watch this space.

AI Summary

Laura E. Niklason and Brady W. Dougan, through Ayabudge LLC, filed an amendment to their Schedule 13D on May 31, 2024, regarding their holdings in Humacyte, Inc. The filing indicates a change in their beneficial ownership of the company's common stock. No specific dollar amounts or new percentage changes were detailed in this amendment.

Why It Matters

This filing signals a potential shift in control or strategy for Humacyte, Inc., as significant stakeholders update their disclosures with the SEC.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, which can introduce volatility.

Key Players & Entities

• Laura E. Niklason (person) — Filing party and beneficial owner
• Brady W. Dougan (person) — Filing party and beneficial owner
• Ayabudge LLC (company) — Entity through which filing parties hold shares
• Humacyte, Inc. (company) — Subject company
• 20240531 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $7.91 — n market at a weighted average price of $7.91 per share for an aggregate sale price o
• $6.4 million — n aggregate sale price of approximately $6.4 million (excluding commissions). On June 3, 20
• $7.42 — n market at a weighted average price of $7.42 per share for an aggregate sale price o
• $1.4 million — n aggregate sale price of approximately $1.4 million (excluding commissions). On June 3, 20
• $7.37 — Stock on the open market at a price of $7.37 per share for an aggregate purchase pri
• $15,100 — gregate purchase price of approximately $15,100 (excluding commissions). Dr. Niklason u
• $6.35 — n market at a weighted average price of $6.35 per share for an aggregate purchase pri
• $15,000 — gregate purchase price of approximately $15,000 (excluding commissions). Dr. Niklason u
• $7.28 — n market at a weighted average price of $7.28 per share for an aggregate sale price o
• $13,500 — n aggregate sale price of approximately $13,500 (excluding commissions). Mr. Dougan us

Filing Documents

• humaschedule13d_a7.htm (SC 13D/A) — 115KB
• 0001818382-24-000085.txt ( ) — 116KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

of the Schedule 13D is hereby amended to be supplemented by the following

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following On April 19, 2024 Dr. Niklason transferred 1,148,240 shares of Common Stock to The Niklason Living Trust for no consideration. Dr. Niklason serves as the sole trustee of The Niklason Living Trust. On May 31, 2024 Ayabudge sold 809,786 shares of Common Stock in the open market at a weighted average price of $7.91 per share for an aggregate sale price of approximately $6.4 million (excluding commissions). On June 3, 2024 Ayabudge sold 190,214 shares of Common Stock in the open market at a weighted average price of $7.42 per share for an aggregate sale price of approximately $1.4 million (excluding commissions). On June 3, 2024 Dr. Niklason purchased 2,050 shares of Common Stock on the open market at a price of $7.37 per share for an aggregate purchase price of approximately $15,100 (excluding commissions). Dr. Niklason used personal funds for such acquisition. On June 4, 2024 Dr. Niklason purchased 2,362 shares of Common Stock on the open market at a weighted average price of $6.35 per share for an aggregate purchase price of approximately $15,000 (excluding commissions). Dr. Niklason used personal funds for such acquisition. On June 4, 2024 Ayabudge sold 1,852 shares of Common Stock in the open market at a weighted average price of $7.28 per share for an aggregate sale price of approximately $13,500 (excluding commissions). Mr. Dougan used the proceeds of the sales by Ayabudge to pay down leverage while providing a mechanism for the purchasers to acquire shares at a time that the Issuer was not conducting a financing transaction. Dr. Niklason is treated as indirectly beneficially owning the shares of Common Stock sold. However, no shares of Common Stock directly owned by Dr. Niklason were sold in these transactions.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended and restated in full as follows

Item 5 of the Schedule 13D is hereby amended and restated in full as follows (a)-(b) Number of shares of Common Stock beneficially owned Laura E. Niklason, M.D., Ph.D. 9,186,901 shares Brady W. Dougan 9,186,901 shares Ayabudge LLC 5,189,288 shares CUSIP No. 44486Q 103 Page 6 of 7 Pages Percent of class Laura E. Niklason, M.D., Ph.D. 7.6% Brady W. Dougan 7.6% Ayabudge LLC 4.4% The percentage ownership was calculated based upon 119,084,353 shares of the Issuer's Common Stock outstanding, as of May 2, 2024, as reported in the Form 10-Q filed with the SEC on May 13, 2024 . Number of shares as to which such person has (i) Sole power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares Ayabudge LLC 0 shares (ii) Shared power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 9,186,901 shares Brady W. Dougan 9,186,901 shares Ayabudge LLC 5,189,288 shares (iii) Sole power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares Ayabudge LLC 0 shares (iv) Shared power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 9,186,901 shares Brady W. Dougan 9,186,901 shares Ayabudge LLC 5,189,288 shares (c) Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days. (d) Not applicable. (e) Not applicable. CUSIP No. 44486Q 103 Page 7 of 7 Pages SIGNATURE After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date June 4, 2024 Laura E. Niklason By s Laura E. Niklason by Dale A. Sander as Attorney-in-Fact Date June 4, 2024 Brady W. Dougan By s Brady W. Dougan by Dale A. Sander as Attorney-in-Fact Date June 4, 2024 Ayabudge LLC By s Brady W. Doug

View Full Filing

View this SC 13D/A filing on SEC EDGAR